Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-17-025146
Filing Date
2017-11-01
Accepted
2017-11-01 19:39:30
Documents
2
Period of Report
2017-11-01

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 15222
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4245
  Complete submission text file 0000899243-17-025146.txt   20998
Mailing Address C/O TARGANTA THERAPEUTICS CORPORATION 225 SOUTH EAST STREET, SUITE 390 INDIANAPOLIS IN 46202
Business Address
Parr Thomas R JR (Reporting) CIK: 0001413008 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38266 | Film No.: 171170344

Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Issuer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations